ClinicaliQ Trial Snapshot
- Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC — Recruiting • Phase I • Oncology • NCT07718243.
- What is being tested: A combination of bexmarilimab (a CSF-1R inhibitor) with nivolumab (a PD-1 checkpoint inhibitor) in patients with advanced melanoma and non-small cell lung cancer who have developed resistance to prior immunotherapy.
- Patient eligibility overview: Adults with histologically confirmed melanoma or NSCLC that has progressed despite previous checkpoint inhibitor treatment; patients must have adequate organ function and performance status suitable for combination immunotherapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour. This is…
Eligibility Snapshot
- : 1. Part A: Histologically proven solid tumour, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient Part B1: Histologically proven NSCLC. * Patient has received at least one but not more than three lines of systemic anticancer therapy for metastatic disease. * Patient has received at least two cycles of immune checkpoint inhibitor and has demonstrated disease progression within 12 weeks of last dose. * Patient has had a benefit to prior immune checkpoint inhibitor defined as greater than 6 months of treatment or partial response. * Patients with actionable EGFR, ALK, or other known genomic alterations must have received at least 1 relevant targeted therapy treatment if available. Part B2: Histologically proven cutaneous melanoma. * Patient has received at least one but not more than three lines of systemic anticancer therapy for metastatic disease. * Patient has received at least two cycles of immune checkpoint inhibitor and has demonstrated disease progression within 12 weeks of last dose. * Patients with BRAF mutations must have received relevant targeted therapy. * Patient has had a benefit to prior immune checkpoint inhibitor defined as greater than 6 months of treatment or partial…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.